Free Trial Information
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
Read More
BioCentury | Oct 17, 2019
Financial News

Innate gains dual listing, tops off fund-raise with private placement

With the $68.8 million raised through a NASDAQ listing and concurrent private placement, Innate plans to commercialize its sole approved cancer therapy and advance its clinical and preclinical pipeline. Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) gained...
Read More
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...Antibody Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 1 (KIR2DL1) / KIR2DL2 / KIR2DL3...
...often also expressed on T cells. It licensed its first-in-class mAb against KIR2DL1, KIR2DL2 and KIR2DL3...
...1 KIR2DL2 - Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 2 KIR2DL3 - Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 3...
Read More
BioCentury | Dec 1, 2017
Clinical News

Innate sees no development path for lirilumab combo therapies

Innate Pharma S.A. (Euronext:IPH) said efficacy data from a Phase I/II trial of lirilumab (BMS-986015, IPH2102) in combination with Opdivo nivolumab to treat head and neck cancers "did not provide clear evidence of benefit to...
Read More
BioCentury | Nov 30, 2017
Clinical News

Innate reports additional Phase I data for IPH4102 in cutaneous T cell lymphoma (CTCL)

In October, Innate Pharma S.A. (Euronext:IPH) reported additional data from the dose escalation portion of the Phase I IPH4102-101 trial. Among 20 patients with relapsed or refractory Sezary syndrome who were killer cell immunoglobulin-like receptor...
Read More
BioCentury | Feb 10, 2017
Clinical News

Lirilumab: Ph II EffiKIR data

Top-line data from the double-blind, French Phase II EffiKIR trial in about 150 elderly AML patients in first complete remission showed that maintenance treatment with 0.1 mg/kg lirilumab every 3 months and 1 mg/kg lirilumab...
Read More
BioCentury | Feb 6, 2017
Clinical News

Innate's lirilumab fails Phase II AML trial

Innate Pharma S.A. (Euronext:IPH) lost EUR 2.05 (16%) to EUR 11.05 on Monday after it said lirilumab ( IPH2102 ) missed the primary endpoint in the Phase II EffiKIR trial to treat elderly patients with acute myelogenous...
Read More
BioCentury | Nov 11, 2016
Clinical News

Lirilumab: Ph I/II CA223-001 data

Data from a cohort of 29 evaluable patients with advanced platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) in the open-label, dose-escalation, international Phase I/II CA223-001 trial showed that IV lirilumab every 4...
Read More
BioCentury | Nov 4, 2016
Clinical News

IPH4102: Preliminary Ph I data

Preliminary data from 16 evaluable patients with KIR3dL2-positive, relapsed or refractory CTCL in the dose-escalation portion of the open-label, international Phase I IPH4102-101 trial showed that 0.0001-1.5 mg/kg doses of IV IPH4102 were well tolerated...
Read More
BioCentury | Oct 10, 2016
Clinical News

Lirilumab: Phase II ongoing

A DSMB recommended for the seventh time continuation of the double-blind, placebo-controlled, French Phase II EffiKIR trial evaluating 0.1 and 1 mg/kg lirilumab based on a safety analysis. The trial completed enrollment of about 150...
Read More
Items per page:
1 - 10 of 26